Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a clinical-stage biopharmaceutical company based in Irvine, California, dedicated to the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Founded in 2016, Tarsus stands at the forefront of eye care innovation with a mission to revolutionize treatments for patients by addressing unmet needs through proven science and new technology.
The company’s flagship product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, was approved by the FDA in 2023. XDEMVY is a pioneering eye drop designed to treat Demodex blepharitis, a common eyelid inflammation caused by an infestation of Demodex mites. Clinical trials involving more than 800 patients demonstrated its efficacy, meeting primary and secondary endpoints with no serious treatment-related adverse events.
Beyond XDEMVY, Tarsus is advancing a diverse pipeline of therapeutic candidates. TP-03 is under investigation for the treatment of Meibomian Gland Disease (MGD), a condition often comorbid with Demodex infestation. TP-04 is being developed for the treatment of papulopustular rosacea (PPR), while TP-05 is explored as a groundbreaking oral prophylactic for Lyme disease and community malaria reduction.
The company’s recent achievements underscore its commitment to advancing therapeutic options in ophthalmology and beyond. Tarsus reported significant clinical improvements in MGD with TP-03, highlighting its potential to address underlying causes of the disease. Additionally, TP-05 showed promising results in early trials, demonstrating high tick mortality rates and suggesting potential as an on-demand prophylactic against Lyme disease.
Tarsus Pharmaceuticals collaborates with leading institutions like Tufts University School of Medicine to bolster its research endeavors. The company is also gaining traction in the marketplace, evidenced by strong quarterly financial results and strategic partnerships with major investment firms such as Goldman Sachs, BofA Securities, and Guggenheim Securities.
With ongoing consumer awareness campaigns such as “Mite Party” for XDEMVY, Tarsus is actively engaging patients and healthcare providers to improve diagnosis and treatment outcomes for Demodex blepharitis. This multi-channel initiative aims to educate the public about the prevalence and impact of Demodex infestation, encouraging patients to seek professional care.
Committed to patient-centric innovation, Tarsus Pharmaceuticals continues to expand its footprint in eye care and explore new therapeutic frontiers, striving to make a significant impact on public health through scientifically driven solutions.
Tarsus Pharmaceuticals (NASDAQ: TARS) reported Q3 2024 financial results, highlighting $48.1 million in XDEMVY® net product sales, an 18% increase over Q2 2024. The company delivered over 41,400 bottles to patients and expanded coverage to more than 80% of covered lives. Q3 net loss was $23.4 million, improving from $39.1 million in Q3 2023. The company maintains a strong cash position of $317.0 million as of September 30, 2024. New clinical data showed significant improvements in Meibomian Gland Disease measures and patient symptoms.
Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Dr. Kate Goodrich, current Chief Medical Officer of Humana, to its Board of Directors. Dr. Goodrich brings over two decades of experience in healthcare innovation and value-based initiatives. As Humana's CMO, she leads clinical operations, healthcare research, and health equity initiatives. Previously, she served as CMO at the Centers for Medicare and Medicaid Services (CMS), where she directed the Center for Clinical Standards and Quality. Dr. Goodrich continues her role as a practicing hospitalist and professor at George Washington University Medical Center while serving on multiple healthcare boards.
Tarsus Pharmaceuticals (NASDAQ: TARS) has scheduled its third quarter 2024 financial results announcement and corporate update for Wednesday, November 13, 2024, at 1:30 p.m. PT / 4:30 p.m. ET. The company will host a live webcast of the event, which will be archived on their website for approximately 90 days following the presentation.
Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. Dr. Yeu, who previously served as Chief Medical Advisor since 2020 and Board member since 2021, will lead the company's new Medical Organization. In her role, she will oversee medical affairs and pharmacovigilance teams, including evidence generation, medical education, and patient safety. Dr. Yeu will maintain her clinical practice at Virginia Eye Consultants while serving as CMO, bringing over two decades of ophthalmology experience to the position.
Tarsus Pharmaceuticals (NASDAQ: TARS) has launched a new direct-to-consumer TV campaign for XDEMVY®, the first and only FDA-approved treatment for Demodex blepharitis. The campaign, titled "Your Mitey Problem," creatively showcases the root cause of the disease through a representation of mites on patients' eyelids.
Demodex blepharitis affects approximately 25 million people in the U.S., or 1 in 12 adults. It occurs when Demodex mites overpopulate on the eyelids, causing symptoms like redness, itching, and inflammation. The campaign aims to educate patients about the disease and encourage them to consult eye care providers about XDEMVY.
The multi-channel campaign is live on connected TV devices and streaming channels, with plans to include digital and social media components. Tarsus expects this innovative approach to reach a greater number of patients in need and drive action among providers and patients.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in the UBS Virtual Ophthalmology Day 2024. Aziz Mottiwala, Chief Commercial Officer, will engage in a virtual fireside chat on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET.
Tarsus, a company focused on addressing unmet needs in eye care through proven science and new technology, will provide a live webcast of the presentation. Interested parties can access the webcast and additional information through the events section of the Tarsus website. A replay of the presentation will be available on the company's website within 48 hours and will be archived for a time.
This participation underscores Tarsus's commitment to revolutionizing treatment for patients, particularly in the field of ophthalmology.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in the 2024 Wells Fargo Securities Healthcare Conference in Boston, MA. The company's CEO and Chairman, Bobby Azamian, M.D., Ph.D., along with CFO and Chief Strategy Officer Jeff Farrow, will engage in an in-person fireside chat on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET.
Tarsus, focused on addressing unmet needs in healthcare, particularly in eye care, will provide a live webcast of the presentation. Interested parties can access the webcast and additional information through the events section of the Tarsus website. A replay will be available within 48 hours and archived for a time.
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1. Year-to-date sales totaled $65.5 million. The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%. Tarsus expanded payer coverage, including Medicare, and is on track to deploy additional sales representatives by Q3 end. Despite the sales growth, Tarsus reported a net loss of $33.3 million for Q2. The company's cash position remains strong at $323.6 million as of June 30, 2024.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced it will host a live webcast on Thursday, August 8, 2024, at 1:30 p.m. PT / 4:30 p.m. ET to report its second quarter 2024 financial results and provide a corporate update. The company, focused on addressing unmet needs in eye care through proven science and new technology, will make the webcast accessible to participants via a provided link. A recorded version of the call will be available on the website shortly after the webcast concludes and will remain archived for approximately 90 days.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced its participation in three upcoming investor conferences. Executives will join fireside chats at the William Blair Growth Stock Conference on June 4, 2024, the Jefferies Global Healthcare Conference on June 5, 2024, and the Goldman Sachs Global Healthcare Conference on June 10, 2024. Attendees include Jeff Farrow, Chief Financial and Chief Strategy Officer, Aziz Mottiwala, Chief Commercial Officer, and Bobak Azamian, CEO and Chairman. Live webcasts will be accessible on Tarsus's website, with replays available within 48 hours.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
What is Tarsus Pharmaceuticals' main focus?
What is XDEMVY?
What are the current projects of Tarsus Pharmaceuticals?
What recent achievements has Tarsus Pharmaceuticals accomplished?
Who are the key partners of Tarsus Pharmaceuticals?
Where is Tarsus Pharmaceuticals headquartered?
What is Demodex blepharitis?
What are the side effects of XDEMVY?
What is TP-03?
How does TP-05 work?
